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Influenza A virus (IAV) is a pathogen of great medical impact. To develop novel antiviral strategies, it is 22 
essential to understand molecular aspects of virus-host cell interactions in detail. During entry, the viral 23 
ribonucleoproteins (vRNPs) that carry the RNA genome must be released from the incoming particle before 24 
they can enter the nucleus for replication. The uncoating process is facilitated by histone deacetylase 6 25 
(HDAC6)1. However, the precise mechanism of shell opening and vRNP debundling is unknown. Here we 26 
show that transportin1 (TNPO1), a member of importin β family proteins, binds to a PY-NLS 2 sequence 27 
motif close to the N-terminus of matrix protein (M1) exposed during acid-priming of the viral core. It 28 
promotes the removal of M1 and induces disassembly of vRNP bundles. Next, the vRNPs interact with 29 
importin α/β (KPNA/KPNB1) and enter the nucleus. Thus, IAV uses dual importin βs for distinct steps in 30 
host cell entry. 31 
 32 
 33 
In the IAV particle, the eight single-stranded, negative-sense RNAs that make up the genome are 34 
individually packaged with a viral polymerase complex into helical vRNPs in which the major protein is 35 
the nucleoprotein, NP. Together with the matrix protein, M1, the vRNPs form a stable, supra-36 
macromolecular complex, the viral core, in which M1 provides a rigid shell around a bundle of vRNPs 3. 37 
The uncoating process is initiated in early and maturing endosomes or macropinosomes after endocytosis 38 
of incoming virus particles 4, 5. The M2 ion channel in the viral envelope allows exposure of the capsid to 39 
low pH and elevated K+, which results in loosening of interactions within the M1 core and between vRNPs 40 
in a process called priming 6. Penetration of the primed core into the cytosol occurs by low pH-triggered, 41 
hemagglutinin(HA)-mediated membrane fusion in late endosomes (LEs) 7-9. In the cytosol, the M1 shell 42 
dissociates, and vRNPs are imported into the nucleus 10-15. In the nucleus, the vRNPs are distributed as 43 
discrete complexes separated from each other 16. Thus, IAV uncoating involves three major steps; priming, 44 
M1 shell disassembly, and vRNP debundling. 45 
We have previously shown that histone deacetylase 6 (HDAC6) serves as a key cellular factor in the M1 46 
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shell disassembly step 1. It binds to unanchored ubiquitin chains and M1 exposed as viral cores emerge on 47 
the cytosolic surface of LEs. It connects the M1 shell to cytoskeleton motors dynein and myosin II, which 48 
promote disassembly of the shell by a cytoskeleton-dependent mechanism related to aggresome processing. 49 
The vRNPs are released into the cytosol where KPNA/KPNB1 mediate their nuclear uptake via nuclear 50 
pore complexes 1, 10, 17. 51 
To identify additional host proteins involved in the cytosolic uncoating and nuclear import steps, we 52 
performed an infection screen using an siRNA library against 70 nuclear pore proteins and genes known to 53 
regulate nucleocytoplasmic transport (Fig.1a and Supplementary Fig. 1) 18-20. We found that infection 54 
was reduced in cells depleted of the nuclear import/export factors CAS (cellular apoptosis susceptibility 55 
protein)/XPO2, KPNB1 (karyopherin-β1, importin β), and several nuclear pore proteins that have been 56 
previously identified as essential for infection (Supplementary Fig. 1)21. Among the novel hits, nuclear 57 
import factor transportin 1 (TNPO1, also known as karyopherin-β2 or Kapβ2) caught our interest because 58 
it is a well-characterised receptor for nuclear import of cellular ribonucleoprotein complexes and RNA-59 
binding proteins such as hnRNP A1 22, 23 many of which carry a recognition sequence termed PY-NLS 2, 24. 60 
Depletion of TNPO1 using siRNA (TNPO1#2) or shRNA reduced the number of infected cells by 66-79% 61 
in A549 and MDCK cells (Fig. 1b-d). Production of infectious virus was reduced by 81% in MDCK cells 62 
(Fig. 1e). Infection could be rescued by expression of TNPO1 using an siRNA-insensitive construct (GFP-63 
TNPO1, Fig. 1f). TNPO1 was needed across various IAV strains X31 (H3N2), WSN (H1N1), and Udorn 64 
(H3N2) of spherical and filamentous morphology (Fig. 1g). TNPO1 was, moreover, required for X31 65 
infection in HeLa cells (Supplementary Fig. 2).  66 
 67 
 68 
 69 
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To define the virus entry step(s) that require TNPO1, we first analysed the intracellular location of incoming 70 
M1 and vRNPs by indirect immunofluorescence (IIF) in control A549 cells at different times after virus 71 
internalisation. At 3hpi, uncoating of the M1 shell had already occurred judging by the broad distribution 72 
of M1 throughout the cytoplasm (Fig. 2a). At 4hpi, NP staining occurred almost exclusively in the nucleus 73 
(Fig. 2b). This indicated that at 3-4hpi the majority of cores had lost their M1 shell and vRNPs had been 74 
released, debundled, and nuclear imported.  75 
 76 
That debundling of vRNPs could, at least in part, occur in the cytoplasm prior to nuclear import was shown 77 
by structured illumination microscopy (SIM) (Fig. 2c). Images taken 1h after synchronised release of 78 
vRNPs from LEs in MEFs showed that in addition to large bright spots containing NP, smaller uniform 79 
NP-containing spots of low brightness were present in the cytoplasm. That these were similar in brightness 80 
and size to the spots in the nucleus known to represent individual vRNPs 16, 25, suggested that debundling 81 
of vRNPs can and does take place in the cytoplasm. 82 
 83 
In TNPO1-depleted cells, M1 was present in bright, cytoplasmic spots. The majority of NP also remained 84 
in cytoplasmic spots that had a distribution similar to viruses trapped by bafilomycin A1 (Baf A1)-treatment 85 
in endosomes (Fig. 2c). Thus, M1 uncoating, vRNP debundling, and vRNP nuclear import were all 86 
inhibited in cells depleted of TNPO1.  87 
 88 
Triple-staining of TNPO1-depleted and KPNB1-depleted cells 2.5hpi provided evidence for a previously 89 
undetected step in the uncoating process; the release of uncoated or partially coated cores from LEs into 90 
the cytosol (Fig. 2d-g). In TNPO1-depleted cells at this time point, NP staining was mainly cytoplasmic 91 
and present in spots of medium brightness that contained variable amounts of M1. Many of these spots did 92 
not colocalise with LAMP1; a marker for endolysosomes (Fig. 2d). In KPNB1-depleted cells, NP-positive 93 
spots of different brightness were also distributed throughout the cytosol, and they did not colocalise with 94 
LAMP1. When cores were synchronously released from LEs in TNPO1-depleted cells 1 and analysed after 95 
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30 min, many of the cytoplasmic NP spots contained M1 in contrast to control cells that displayed small 96 
NP spots in the nucleus or larger spots in the cytoplasm devoid of M1 (Supplementary Fig. 3). Taken 97 
together, these results indicated that TNPO1 is required for a step involving removal of M1 from cores that 98 
have been released into the cytosol.  99 
 100 
Judging by the brightness of the NP-positive spots in TNPO1-depleted cells compared to nuclear vRNPs in 101 
control cells, the vRNPs were still associated with each other. When KPNB1 was depleted, vRNPs failed 102 
to enter the nucleus 15, 16, 21 but uncoating of cytoplasmic cores proceeded further than in TNPO1-depleted 103 
cells; M1 was no longer associated with NP-containing spots (Fig. 2d). The smaller spot size indicated that 104 
vRNPs had been debundled (Fig. 2d, f). Taken together, these results indicated that TNPO1 removed M1 105 
from incoming cores and debundled the vRNPs in the cytosol. While KPNB1 is clearly essential for nuclear 106 
import 16, 21, it was dispensable for core uncoating and debundling. 107 
 108 
Next, we used synchronised penetration of cores into the cytosol of A549 cells by inducing fusion of pre-109 
primed, cell surface-bound viruses with the plasma membrane (acid-bypass) 6, 26 (Supplementary Fig. 4a). 110 
Fusion/hemifusion was confirmed by lipid mixing 25. Depletion of TNPO1 and KPNB1 inhibited vRNP 111 
import by 68% and 79%, respectively (Fig. 2h, Supplementary Fig. 4b). In half of TNPO1-depleted cells 112 
M1-uncoating failed to occur (Fig. 2h, Supplementary Fig. 4a). In TNPO1-depleted MDCK cells, M1-113 
uncoating was reduced by 75% compared to control cells but fusion/hemifusion was unaffected (Fig. 2i, j). 114 
M1-uncoating could be rescued by ectopic expression of shRNA-insensitive GFP-human TNPO1 (Fig. 2k). 115 
Taken together, these findings confirmed that TNPO1 was involved in the dissociation of M1 from 116 
incoming cores, whereas KPNB1 nuclear imported vRNPs 21. In further support of a role for TNPO1 in 117 
M1-uncoating, overexpression of TNPO1 increased M1-uncoating (Supplementary Fig. 4c), and that of a 118 
recombinant protein carrying the hnRNP A1 M9-NLS 22, 23 caused a reduction (Supplementary Fig. 4c). 119 
We concluded that TNPO1’s role in the dissociation of M1 from incoming cores was associated with the 120 
PY-NLS binding function.  121 
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   122 
IIF showed that TNPO1 in control cells is localised in the nucleus with a few spots in the cytoplasm (Fig. 123 
3a). Fifteen min after synchronous release of particles from LEs in MEFs 1, we could observe that some of 124 
the NP-containing spots in the cytoplasm contained TNPO1 (Fig. 3a, WT). Spots were also weakly stained 125 
for M1. This indicated that TNPO1 associates with incoming cores and with vRNP bundles that have 126 
residual M1. That TNPO1 also colocalised with M1/NP-positive spots in HDAC6 -/- MEFs (Fig. 3a, 127 
HDAC6 -/-) indicated that TNPO1 association with cores takes place in the absence of HDAC6 and 128 
aggresome processing. In these spots, the staining for M1 was stronger suggesting that TNPO1 can bind to 129 
more intact-looking cores but is unable to remove M1 efficiently without HDAC6 action. 130 
 131 
When virus was primed at pH 5.6 and 120 mM KCl, lysed, incubated with His-TNPO1 for pull-down, M1 132 
was found to co-precipitate (Fig. 3b). However, only trace amounts were precipitated from lysates prepared 133 
from unprimed virus. When cells were infected for 2.5h in the presence or absence of NH4Cl, M1 co-134 
precipitated less efficiently with TNPO1 in the NH4Cl-treated cells compared to non-treated cells 135 
(Supplementary Fig. 5a, b).  136 
 137 
When examining the amino acid sequence of M1, we observed short sequences close to the N-terminus that 138 
resemble known elements to the PY-NLSs recognised by TNPO1 in cellular substrates 27. These elements 139 
are referred to as epitopes 1, 2, and 3 (Fig. 3c), of which the glycine residue in epitope 1 is critical for 140 
TNPO1 recognition 2. Sequences similar to epitopes 1 and 2 are conserved among M1 of IAV strains. The 141 
crystal structure of M128 shows that they are on the surface of M1. We hypothesised that in primed cores, 142 
they may serve as a binding motif for TNPO1. The hypothesis was tested by generating a mutant IAV WSN 143 
(H1N1) strain in which Gly 18 in M1 was replaced with alanine by reverse genetics 29. When normalised 144 
for the same number of viruses, the G18A mutant virus reached 2% of the infectivity observed for the WT 145 
virus (Fig. 3d).  146 
 147 
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When His-TNPO1 was pulled-down after incubation with pre-primed virus lysates containing either the 148 
G18A virus or the WT control virus, the M1 of G18A precipitated less efficiently (Fig. 3e). This indicated 149 
that Gly 18 is essential not only for infection but also for efficient TNPO1 association. We also found that 150 
Gly 18 is an epitope of the HB-64 monoclonal antibody used to detect M1-uncoating (Supplementary Fig. 151 
6), indicating that acidification exposes the PY-NLS. 152 
 153 
We solved the crystal structure of the neutral pH form of M1 with the G18A mutation expressed in E. coli, 154 
and compared it to the structure of the WT protein. The main difference between the WT structure was seen 155 
around the PY-NLS sequence motif. A cavity formed by loops L1 (15-19) and L3 (49-53) in WT M1 was 156 
absent in G18A (Fig. 3f-h, Supplementary Fig. 7a, Supplementary Table 1). The 1. 9 Å resolution G18A 157 
M1 N-terminal domain structure, though monomeric in solution, forms the so called face-to-back dimer in 158 
the crystal lattice representing the neutral pH oligomeric state of M1 similar to PDB entries 1EA3 or 5V8A 159 
30, 31 (Supplementary Fig. 7b). Glycine 18 and surrounding amino acid residues are masked in this face-160 
to-back M1-M1 interface crystallised at neutral pH, but are exposed in acidified M1 crystals 28 161 
(Supplementary Fig.7c). This may explain why M1 in lysates of primed viruses engage TNPO1 better 162 
than unprimed ones (Fig. 3b). During virus entry, priming may thus allow subsequent TNPO1 binding to 163 
M1. It may explain why unprimed viruses are not uncoated 6 and why TNPO1 does not interfere with the 164 
functions of newly-synthesised M1 in infected cells. 165 
 166 
In summary, our results lead to a more detailed step-by-step model for IAV uncoating (Fig. 4). After viral 167 
uptake into endosomes, the M2 cation channels open resulting in influx of protons and K+ ions that loosens 168 
interactions stabilising the core 6 and triggers a conformational change in M1 that exposes the PY-NLS 169 
close to the N-terminus. Following viral fusion in LEs, the core is exposed to cytosolic factors. HDAC6 170 
binds to shell-associated, unanchored ubiquitin chains 1. Together with other components of the aggresome 171 
processing machinery, HDAC6 releases the shell from the endosome surface and ruptures it. This process 172 
depends on forces generated by microtubules and microfilaments and the corresponding motors, dynein 173 
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and myosin II. At the same time, TNPO1 associates with the PY-NLS exposed in the primed M1. TNPO1’s 174 
main role is to promote removal of vRNP-associated M1, which allows dissociation of vRNPs from each 175 
other. Some of the removed M1 may enter the nucleus with TNPO1. KPNA and KPNB1 bind to the 176 
classical NLS in NP resulting in nuclear import of fully or partially debundled vRNPs. Thus, the primary 177 
role of TNPO1 is M1 removal and debundling of vRNPs in the cytosol. 178 
 179 
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Materials and Methods 199 
 200 
Cells 201 
 202 
A549, Madin-Darby Canine Kidney (MDCK), HEK293T, and HeLa cells were obtained from the American 203 
Type Culture Collection (ATCC). Mouse embryonic fibroblasts (MEFs) were isolated from embryonic day 204 
13.5 from male embryos of wild type and HDAC6 -/- mice 32. For some acid-bypass experiments, the plate 205 
wells were coated with 0.01% poly-L-lysine prior to use. All cells were maintained in Dulbecco’s modified 206 
Eagle’s medium (DMEM)(Invitrogen), supplemented with 10% fetal calf serum (FCS) under 5% CO2 at 207 
37°C. MDCK cells capable of inducible expression of shRNA targeting the canine TNPO1 sequence 208 
GCAGTGCCTTTGCTACCTTAG was a kind gift from Ben L. Margolis 33. 209 
 210 
Viruses 211 
 212 
IAV X31 strain (an H3N2 reassorted strain derived from PR8 and A/Hong Kong/1/68 strains) was 213 
purchased from Virapur (CA, USA). To propagate X31 virus, 60 pathogen-free chicken eggs were 214 
inoculated with the virus and incubated at 33-37°C for 2 days. The allantoic fluid was harvested and 215 
clarified by low-speed centrifugation, which was then concentrated by high-speed centrifugation. To further 216 
concentrate the virus, two rounds of 10-40% sucrose gradient centrifugation were performed, viral bands 217 
harvested, pooled and re-suspended in formulation buffer (40% sucrose, 0.02% BSA, 20 mM HEPES pH 218 
7.4, 100 mM NaCl, 2 mM MgCl2). The viral titer was determined as 1.0 x10
10 TCID50 infectious units/ml 219 
in MDCK cells. The virus was aliquoted and stored in formulation buffer at -80 ̊C until use. IAV WSN 220 
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(A/WSN/1933) (H1N1) strain was propagated in MDCK cells and purified by sucrose gradient 221 
ultracentrifugation as previously described 6. IAV Udorn (A/Udorn/72) (H3N2) strain was a kind gift from 222 
Jovan Pavlovic. TCID50 assays were performed as described elsewhere. 223 
 224 
 225 
Reagents 226 
 227 
Hybridoma cell lines producing monoclonal antibodies specific for IAV M1 anti-M1 (HB-64) and NP (HB-228 
65) were purchased from ATCC. Anti-IAV M1 (goat, #1311) was purchased from Virostat. Anti-TNPO1 229 
(mouse, ab10303), anti-TNPO1 (rabbit, ab191539), anti-LAMP1 (rabbit, ab24170) antibodies were 230 
purchased from abcam, anti-CAS (sc-1708) from Santa Cruz. Anti-importin β (clone 31H4) monoclonal 231 
antibody was purchased from Sigma-Aldrich, anti-His monoclonal antibody from Sigma-Aldrich, anti-GFP 232 
monoclonal antibody (JL-8) from Clontech. The mouse monoclonal anti-A/WSN/33 HA (clone H15-B9-233 
22 34, The Wistar Institute, Philadelphia, US) was a kind gift from Silke Stertz. The anti-IAV M1/M2 234 
monoclonal antibody (E10) was a kind gift from Jovan Pavlovic. Lipofectamine RNAiMax, lipofectamine 235 
2000 or 3000, OPTI-MEM was purchased form Invitrogen. Bafilomycin A1, cycloheximide, doxycycline, 236 
imidazole, TPCK-Trypsin, 0.1% poly-L-lysine, fibronectin were purchased from Sigma Aldrich. Ni-NTA 237 
agarose resin was purchased from Qiagen. µCLEAR 96-well optical microplates plates (#655090) were 238 
purchased from Greiner Bio-one. 239 
 240 
IAV reverse genetics 241 
 242 
Reverse genetics using the 8 plasmid rescue system 29 (a kind of gift of Robert Webster) was performed as 243 
follows: per 60mm dish of HEK 293T cells, 1 µg each of purified plasmid DNA (i.e. pHW-2000-M, -NP, 244 
-HA, -NA, -PB1, -PB2, -PA,- NS1 (WSN)) were co-transfected using lipofectamine 2000. Eighteen h later 245 
the medium was exchanged to DMEM containing 0.2% BSA, 0.1% FCS, 2mM L-glutamine, 1µg/ml 246 
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TPCK-Trypsin. Virion-containing supernatants were harvested at 48 h post-transfection. The mutant virus 247 
and the corresponding WT virus was recovered in the medium of the transfected cells, and quantitated using 248 
an IIF-based cell binding assay.  249 
 250 
siRNA transfections 251 
 252 
siRNAs (AllStars Negative control, TNPO1#1 (Hs_TNPO1_7:CAGCATGTTAAGCCTTGTATA), 253 
TNPO1#2 (Hs_TNPO1_2:CAGAATTGGCCTGACCTCTTA), TNPO1#3 254 
(Hs_TNPO1_6:CTGGAACAACTTAATCAGTAT), Hs_ATP6V1B2_3 255 
(CACGGTTAATGAAGTCTGCTA), Hs_KPNB1_1 (TCGGTTATATTTGCCAAGATA) were purchased 256 
from Qiagen. Reverse transfection was done using Lipofectamine RNAiMax and OPTI-MEM at a final 10 257 
nM siRNA concentration. The cells were maintained in a 5% CO2 incubator at 37°C for 3 days before 258 
experiments were performed.  259 
 260 
RNAi screening 261 
 262 
Seventy host genes regulating nucleocytoplasmic transport (3 siRNAs per gene) were distributed across 263 
four plates in a 96-well plate format. siRNAs (10 µl of a 100 nM stock in OPTI-MEM; Invitrogen) were 264 
added to the transfection reagent (0.1 µl RNAiMax in 20 µl OPTI-MEM) in wells of 96-well plates and 265 
incubated at room temperature for 45 min. Then, 1,500 A549 cells were added to each well in 70 µl of 266 
growth medium. 62 h after transfection, cells were infected with MOI≈0.2-0.5 of IAV X31 in infection 267 
medium for 10 h. Cells were fixed with 4% formaldehyde in PBS, stained for NP, and DNA was stained 268 
with DAPI. Cells were automatically imaged using a 20× objective on a BD pathway 855 microscope. The 269 
percentage of infected cells  was analysed by the Infection Counter, a MatLab-based program, as 270 
previously described 25. The Allstars Negative Control was included three times on each plate. All siRNAs 271 
used for screening were designed by and purchased from Qiagen. 272 
 12 
 
 273 
IAV entry, infection and replication assays 274 
 275 
Virus assays were performed in infection medium (DMEM, 50 mM HEPES buffer, pH 6.8, 0.2% BSA). 276 
The virus entry assays were carried out as per the protocols previously described 1, 25. The detection time-277 
point for infection (NP expression) was 7 hpi. The assays were performed either in 24-well plates for 278 
confocal imaging (using 100× and 63× objectives) and FACS analysis, or 96-well optical bottom plates for 279 
automated imaging. For assays using MEFs the surface of plates/coverslips was coated with fibronectin (50 280 
μg/ml in PBS) for 30 min prior to the experiment. Coverslips were mounted on slides with Immu-Mount 281 
(Thermo Fisher Scientific). For rescue experiments using A549 cells, siRNA TNPO1#2 was transfected 282 
using RNAiMax. Two days later an siRNA-resistant construct pEGFP-TNPO1 was transfected using 283 
lipofectamine 2000. Eighteen h later, the infection assay was performed and cells were fixed at 6.5 hpi, 284 
stained for NP and analysed by FACS. The proportion of NP-positive cells in the low to mid GFP-285 
expressing population was analysed using the FlowJo software. High GFP-expressing cells were not 286 
analysed. For IAV replication assays, MDCK cells were induced of TNPO1 shRNA expression by the 287 
addition of 1 µg/ml doxycycline to the growth medium for 3 days. IAV X31 was then infected at MOI=0.01 288 
for 1h after which the medium was replaced with MEM supplemented with 0.1% FCS, 0.2% BSA, 100 289 
U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 1 µg/ml TPCK-Trypsin. Supernatants 290 
were harvested at 24 hpi (and 48 hpi) and the infectious titer was analysed by TCID50 on MDCK cells. 291 
 292 
Synchronised penetration assay at LEs (NH4Cl washout) 293 
 294 
Cells grown on coverslips in 24-well or 4-well plates were bound with 1 µl of X31 (MOI≈100) per well in 295 
infection medium for 1 h on ice. The cells were washed and warmed to 37°C to allow endocytosis for 20 296 
min in the presence of 1 mM cycloheximide, after which the medium was replaced with STOP medium 297 
(DMEM, 50 mM HEPES, pH adjusted to 7.4, supplemented with 20 mM NH4Cl immediately before use) 298 
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and incubated further for 1 h to accumulate virus particles in the LEs. The medium was replaced with 299 
infection medium with cycloheximide to allow endosomal re-acidification and viral penetration and cells 300 
were fixed at indicated time points, and processed for IIF 1, 35. 301 
Synchronised fusion assay at the plasma membrane (acid bypass)  302 
Labeling of the virus with lipophilic fluorescent dyes (R18/SP-DiOC18(3)) was done as previously 303 
described 1, 25. In brief, 50 μl of X31 stock was diluted in 750 μl PBS, to which a premixture of R18 and 304 
SP-DiOC18(3) was added with vigorous mixing, at a final concentration of 0.4 μM and 0.2 μM, respectively. 305 
The mixture was rocked for 1 h at room temperature in the dark, and filtered through a syringe filter with a 306 
0.22 μm pore size (Millipore) to remove unbound dye and aggregates. Cells were trypsinised, counted and 307 
50,000 cells were taken into each eppendorf tube in a volume of 50 μl. Fifty μl of R18/SP-DiOC18(3) 308 
labelled virus was added and the mixture was incubated on ice for 30 min with tapping every 10 min to 309 
allow for virus binding to cells. Cells were washed with cold infection medium by low speed centrifugation 310 
to remove unbound virus particles. After removal of the supernatant, 300 μl of pre-warmed pH 7.4 medium 311 
or medium buffered to pH 5.0 with 50 mM citrate buffer were added to the cells, mixed and incubated at 312 
37°C in a water bath with circulation in a floating device. After 2 min, cells were fixed immediately by 313 
direct addition of 300 μl of 8% formaldehyde in PBS. After washing, the cells were resuspended in 250 μl 314 
of FACS buffer, and analysed by FACS.  315 
Acid bypass M1-uncoating, vRNP nuclear import assays 316 
To detect M1-uncoating and NP expression by inducing viral fusion at the plasma membrane, acid-bypass 317 
uncoating and infection assays were performed as previously described 1. X31 stock (5 μl, MOI≈500 for 318 
uncoating assay and 2 μl, MOI≈200 for nuclear import assay/well of a 96-well optical plate) was pre-bound 319 
to cells on ice for 1 h. Cells were washed with cold infection medium to remove unbound virus. After 320 
removal of infection medium, 500 μl of pre-warmed pH 6.8 medium or medium buffered to pH 5.0 with 321 
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citrate buffer was added. The plates were incubated in a 37°C water bath on top of a metal block touching 322 
the plate bottom directly. After 2 min, the cells were washed 2 times with cold infection medium and 323 
incubated with STOP medium. Cells were further incubated at 37°C for 3 min for the M1-uncoating assay, 324 
or for 45 min for the nuclear import assay, on a prewarmed metal plate in 5% CO2, 37°C, after which they 325 
were fixed and processed for confocal microscopy. M1-uncoating was detected by the characteristic 326 
increase in the immunostaining with anti-M1 monoclonal antibody (HB-64) after uncoating. For M1-327 
uncoating rescue assays in TNPO1 shRNA-expressing MDCK cells, pEGFP-TNPO1 or pEGFP-C3 328 
(control) constructs was transfected 2 days after shRNA induction by doxycycline. Twenty h after 329 
transfection, cells were trypsinised, counted and 30,000 cells were taken in each eppendorf tube in a volume 330 
of 50 μl. Three μl (MOI≈100) of X31 in 50 μl infection medium was added to the cells, mixed and incubated 331 
on ice for 30 min with occasional tapping. Cells were washed with cold infection medium by low speed 332 
centrifugation to remove unbound virus particles. After removal of the supernatant, 300 μl of pre-warmed 333 
pH 6.8 medium or medium buffered to pH 5.0 with 50 mM citrate buffer were added to the cells and 334 
incubated at 37°C for 2 min in a water bath with circulation on a floating device. Further, 300 µl of pre-335 
warmed pH 6.8 medium or pH 8 medium (to re-neutralise the pH 5.0 medium) was added, and incubated 336 
for 3 min at 37°C. Cells were fixed by directly adding 600 μl of 8% formaldehyde in PBS. After washing, 337 
the cells were resuspended in 250 μl of FACS buffer, stained with HB-64 (1:3000) and analysed by FACS.  338 
Recombinant protein purification 339 
 340 
His-tagged human TNPO1 was expressed at 21°C in SG13 bacterial cells. The cell pellet was lysed by 341 
French Press twice and incubated with Ni-NTA agarose for 2 h at 4°C 36. The purified protein was eluted 342 
with imidazole-containing buffer (50 mM Na2HPO4, 250 mM NaCl, 400 mM imidazole, 5 mM β-EtSH) 343 
followed by gel filtration in gel filtration buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT) with 344 
a Superdex 200 10/300 GL column (GE Healthcare). His-tagged MBP proteins were purified from 345 
pOPINM-HisMBP-mouse HDAC6 constructs. Mouse HDAC6 proteins were expressed in Sf9 insect cells 346 
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and purified with Ni-NTA agarose (Qiagen) and gel filtration with a Superdex 200 16/60 column. Purified 347 
protein was digested with 3C protease (Sigma Aldrich) overnight on ice, then purified with Amylose resin 348 
(NEB). After the 3C cleavage step, His-tagged MBP was eluted from the resin with 10 mM maltose-349 
containing buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10 mM maltose, 2 mM TCEP) and gel filtrated 350 
in gel filtration buffer (20 mM Tris, pH 7.5, 200 mM NaCl, 2 mM TCEP). 351 
 352 
Pull-down assay from purified IAV extracts 353 
 354 
Purified IAV X31 was treated with/without priming for 30 min at 37°C using either neutral buffer (30 mM 355 
HEPES, 30 mM MES, pH 7) or priming buffer (30 mM MES pH 5.6, 120 mM KCl) 6. After priming, IAV 356 
were lysed with Cytoskeleton (CSK) buffer (10 mM PIPES pH 6.8, 100 mM NaCl, 300 mM Sucrose, 3 357 
mM MgCl2, 1 mM EGTA, 0.1% Triton X-100) supplemented with a protease inhibitor cocktail (Roche). 358 
Lysis was performed by incubating for 30 min on ice with occasional pipetting. The lysed virus was used 359 
for Ni-NTA agarose pull-down analysis. Four µg of purified His-tagged human TNPO1 protein was mixed 360 
with the virus lysate. Purified His-tagged maltose binding protein (MBP) was used as negative control. The 361 
mixture was incubated for 3 h at 4°C on a rotary shaker after which 20 µl of a 50% slurry of Ni-NTA 362 
agarose beads (equilibrated with CSK buffer containing 20 mM imidazole and 1% BSA) was added and 363 
rotated for 30 min at 4°C. The samples were spun down at 3,000 rpm for 1 min at 4°C, beads were washed 364 
once with CSK buffer containing 20 mM imidazole, 1% BSA, followed by two washes in CSK buffer 365 
containing 20 mM imidazole. Finally, the precipitate was eluted with 15 µL of CSK buffer containing 200 366 
mM imidazole. The samples were lysed in Laemmli buffer and boiled for 5 min at 95°C, and loaded onto 367 
a BoltTM 4-12% Bis-Tris Plus Gel (Thermo Fisher Scientific), and run in MES running buffer for 35 min at 368 
200 V. The protein samples were transferred onto immobilon-P PVDF membranes (Merck) using a Trans-369 
Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-rad) according to instructions by the manufacturer. 370 
After transfer, the PVDF membrane was washed for 5 min in 1x TBST buffer, then blocked with 5% skim 371 
milk (Sigma) in 1xTBS buffer for 1 h at room temperature. Primary antibodies against M1 (HB-64) and/or 372 
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His-tag were used at 1:3000 and 1:1000 dilution, respectively. The primary antibody reaction was carried 373 
out at 4°C overnight, then the membrane was washed three times with 1x TBST buffer for 5 min each. 374 
Secondary antibodies (anti-mouse IgG-HRP conjugated or anti-goat IgG-HRP conjugated) were used at 375 
1:3000 dilution in 5% skim milk in 1x TBS buffer and incubated for 1 h at room temperature and washed 376 
with 1x TBST buffer three times for 15 min each. The signal was detected using SuperSignalTM West Pico 377 
PLUS Chemiluminescent Substrate (Thermo Fisher Scientific), exposed on an X-ray film (Fuji Film) and 378 
developed with a developer machine. 379 
 380 
Immunoprecipitation assay 381 
 382 
A549 cells growing in 60 mm dishes were washed with infection medium and bound with 10µl (MOI≈50) 383 
of X31 for 45 min on ice. The cells were washed and incubated in warm infection medium or STOP medium 384 
at 37°C for 2.5 h, after which the cells were washed in PBS, harvested with a cell scraper and centrifuged 385 
at 3,000 rpm for 5 min using a benchtop microcentrifuge. The supernatant was removed and the cell pellet 386 
was lysed in 100µl of CSK buffer, sonicated and incubated for 60 min on ice with occasional vortexing. 387 
The lysate was centrifuged at 3,000 rpm for 5 min after which the supernatant was reacted with anti-TNPO1 388 
antibody (mouse, 1 µg) or mouse IgG (1 µg) and rotated for 2 h at 4°C. Then, 20 µl of a 1:1 slurry of Protein 389 
A/G Agarose (Pierce) in CSK buffer was added and rotated for 1 h at 4°C. The beads were washed three 390 
times in CSK buffer by pelleting at 3,000 rpm for 5 min at 4°C, and processed for SDS-PAGE and Western 391 
blotting as described for the pull-down assay. 392 
 393 
Molecular cloning 394 
 395 
Plasmid constructs used were pEGFP-M9NLS, -M9NLS mutant and pQE-Trn136. pEGFP-TNPO1 was a 396 
kind gift of Woan-Yuh Tarn. To generate the TNPO1#2-resistant construct pEGFP-TNPO1-Res1, a primer 397 
(GCAACAAAAACTGGAACAACTGAATCAGTATCCAGAC) was used to introduce a silent point 398 
 17 
 
mutation into the pEGFP-TNPO1 sequence by mutagenesis PCR. GFP-M1 was constructed by inserting 399 
IAV (A/WSN/1933(H1N1) M1 WT sequence amplified by PCR using the primer pair (fwd: 400 
CGCCTCGAGATGAGTCTTCTAACCGAGGTCGAA, rev: 401 
GGAATTCTCACTTGAATCGTTGCATCTGC), into the pEGFP-C3 vector via XhoI/EcoRI restriction 402 
sites. The point mutations G18A, P19A, L20A, K21A were further introduced using the GFP-M1 as 403 
template: The primers used for each point mutant were G18A (fwd: GTCCCGTCAGcCCCCCT, 404 
rev:GATAGAGAGAACGTACGTTTCGACCTC), P19A (fwd: CCCGTCAGGCgCCCTCAAAGC, rev: 405 
ACGATAGAGAGAACGTACGTTTCGACCTC), L20A (fwd: GTCAGGCCCCgcCAAAGCCGAG, rev: 406 
GGGACGATAGAGAGAACGTACGTTTCGACC), K21A (fwd: GGCCCCCTCgcAGCCGAGATCG, 407 
rev: TGACGGGACGATAGAGAGAACGTACGTTTC). All constructs were verified by sequencing. 408 
 409 
Cloning, expression and purification of G18A M1-N 410 
 411 
A DNA template encoding matrix protein M1 from IAV A/WSN/1933(H1N1) (GenBank accession number 412 
CY034133.1) was gene synthesised by GeneArt. The G18A M1 1-158 (G18A M1-N) sequence was 413 
generated by PCR and cloned into pOPINF using In-Fusion cloning 37. This construct, pOPINF G18A M1-414 
N, yields an N-terminal His x6 tag with a 3C protease site followed by the M1-N sequence that corresponds 415 
to Uniprot P05777 except for the single point mutation G18A. Protein expression was performed in E.coli 416 
BL21 DE3 cells via auto-induction at 20°C. Cell extracts were obtained using an EmulsiFlex-C3 (Avestin) 417 
cell disruptor and clarified via centrifugation and filtration. The target protein was first purified over nickel 418 
Superflow (Qiagen) resin followed by gel filtration on a S75 HiLoad 16/60 column (GE Healthcare). His-419 
tagged G18A M1-N protein was concentrated to 9.1 mg/ml in 20 mM Tris, pH 7.5, 200 mM NaCl, 2 mM 420 
TCEP and 0.02% NaN3. 421 
 422 
Crystallisation, data collection and structure determination 423 
 424 
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N-terminally His-tagged IAV M1 protein consisting of residues 1-158 (M1-N) was crystallised using the 425 
sitting-drop vapor diffusion method at 20°C with a Phoenix nano-liter dispensing robot (Art Robbins). 426 
One hundred nl of M1-N protein at 9.1 mg/ml in protein buffer (0.02 M Tris, pH 7.5, 0.2 M NaCl, 2 mM 427 
TCEP, 0.02% NaN3) was mixed with 100 nl of crystallisation buffer (30 % (w/v) EDO_P8K, 0.1 M MB2 428 
pH 7.5, 10% NPS; Molecular Dimensions Morpheus HT-96 C6). Long rod-like crystals were obtained 429 
after 5-10 days, which were harvested and cryo-cooled in liquid nitrogen. X-ray data collection was 430 
carried out at the SLS PX-II beamline in Villigen, Switzerland, at 100 K. IAV M1-N protein crystals 431 
diffracted to 1.9 Å and belonged to space group P1 at pH 7.5 with two molecules per unit cell. Diffraction 432 
data was integrated and scaled using the XDS program package 38 and the M1-N structure was solved by 433 
the molecular replacement method with PHASER 39 using available wild-type M1 structures as search 434 
models. The structure was then manually completed and further improved by the crystallographic 435 
simulated annealing routine followed by individual B-factor refinement in PHENIX 40. The structure was 436 
finalized by several rounds of manual rebuilding in COOT and refinement in BUSTER 41. Structure 437 
validation was carried out using tools implemented in COOT. Structural images for figures were prepared 438 
with PyMOL (https://pymol.org). Atomic coordinates and structure factors have been deposited in the 439 
Protein Data Bank under accession code 6I3H. 440 
 441 
 442 
Image acquisition 443 
 444 
For the initial RNAi screening, automated image acquisition was performed using 96-well optical bottom 445 
plates with a BD Pathway microscope using a 10x objective. Subsequent automated image acquisition was 446 
performed with a 10x objective using Molecular Devices ImageXpress Micro imaging system or Yokogawa 447 
CV7000. Four (2x2) to 9 (3x3) images were acquired from each well for each fluorescence channel 448 
depending on the instrument, typically resulting in the counting of more than 3,000 cells in the control 449 
sample. High-resolution images were acquired on inverted microscopes Zeiss LSM 510 Meta, LSM 780, 450 
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Leica SP8 for confocal imaging, or Deltavision OMX for structured illumination super-resolution 451 
microscopy (SIM).  452 
 453 
Image analysis 454 
 455 
Images were processed in Cell Profiler 3.0.0 to identify areas of M1, NP and LAMP1 signal and to measure 456 
the intensity and shape parameters of these objects for colocalisation analysis. Briefly, images were median 457 
filtered to remove noise and objects were identified in the M1, NP and LAMP1 channels using an adaptive 458 
Otsu thresholding method. The M1 and NP objects were masked by the identified LAMP1 objects to create 459 
images showing M1 or NP signals from within or outside of LAMP1-positive regions. The intensity, shape 460 
and location of these objects were then measured. To identify individual cells, the signals from the M1, NP 461 
and LAMP1 channels were added together and smoothed with a Gaussian filter creating a smoothed 462 
integrated intensity image of all the three signals. The Hoechst stained cell nuclei were then identified as 463 
objects and used as the seed points to distinguish cell boundaries using the previously created smoothed 464 
integrated intensity image. Measurement of M1 and NP object intensities were then made inside and outside 465 
of the nuclei area. The individual identified M1 and NP objects were then combined for each image to 466 
create a mask of all M1 and/or NP signal areas inside or outside of LAMP1 signal areas, and then these 467 
were dilated by 2 pixels. Colocalisation analysis (rank-weighted) was then performed using the raw M1 468 
and NP images masked by either of these masks.  469 
 470 
Phenotypic analysis of the M1 uncoating dataset was performed by supervised machine learning software, 471 
the Advanced Cell Classifier 25. Confocal images for analysis were acquired using a 63× oil (NA 1.40) 472 
objective at 1024×1024 pixels per image with a Leica SP8 microscope.  473 
Statistical analysis  474 
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Data are represented as mean ± SD. For all analyses, multiple independent experiments (N≥3) were carried 475 
out. Statistical analysis was performed using Prism 7 (GraphPAD Software Inc.) software.  476 
Data availability 477 
The data that support the findings of this study are available from the corresponding author upon request. 478 
Atomic coordinates and structure factors of G18A M1-N have been deposited in the Protein Data Bank 479 
under accession code 6I3H.  480 
 481 
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 582 
Figure Legends 583 
 584 
Fig.1 TNPO1 is required for IAV infection. 585 
(a) Heatmap showing the top 19 hit genes (out of 70) from the nucleocytoplasmic transport factor siRNA 586 
screen. The screen was repeated independently three times using IAV X31 strain in A549 cells. The read-587 
out for infection was done by IIF against NP (HB-65). The average infection inhibition of individual 588 
siRNAs, and that of the three independent siRNAs are shown.  589 
(b) IAV infection is reduced in TNPO1-depleted cells. A549 cells treated with AllStars Neg control siRNA 590 
or with siTNPO1 or siATP6V1B2 (a vacuolar-ATPase subunit, used as a positive control) were infected 591 
with IAV and stained for NP (HB-65) at 10 h.p.i. Scale bars; 200 µm. Nuclei were stained with DAPI. The 592 
experiments were repeated independently multiple times (n>3) with similar results. 593 
(c) Reduced IAV infection in A549 cells transfected with siTNPO1#2 or siATP6V1B2. TNPO1-depletion 594 
was confirmed by Western blotting. n=3 biologically independent experiments. P value was determined 595 
using two-sided, unpaired t-test. 596 
(d) Reduced IAV infection in MDCK cells expressing TNPO1 shRNA. TNPO1-depletion was confirmed 597 
by Western blotting. n=4 biologically independent experiments. P value was determined using two-sided, 598 
unpaired t-test. 599 
(e) Reduced IAV replication in TNPO1-depleted MDCK cells. Three days after TNPO1 shRNA induction 600 
by doxycycline, the cells were infected with X31 (MOI=0.01) after which the supernatant was harvested at 601 
24 hpi and the IAV titre was determined by TCID50 assay. n=3 biologically independent experiments. 602 
(f) IAV infection is rescued in TNPO1-depleted A549 cells by an siTNPO1-insensitive construct expressing 603 
GFP-TNPO1. n=3 biologically independent experiments.  604 
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(g) TNPO1 is required for infection of multiple IAV strains. siRNA-treated cells were infected with X31 605 
(H3N2), WSN (H1N1), and Udorn (H3N2) strains. siATP6V1B2 was used as a positive control. n=3 606 
biologically independent experiments. All bar graphs show the mean and SD. 607 
 608 
Fig.2 TNPO1 promotes M1-uncoating from incoming cytoplasmic vRNPs. 609 
(a) TNPO1-depletion inhibits M1-uncoating. M1 (HB-64) staining of IAV-infected A549 cells at 3 hpi. 610 
Scale bars; 10 µm. n=3 independent experiments gave similar results. 611 
(b) IAV vRNP debundling can occur in the cytoplasm prior to vRNPs reaching the nuclear pore. NP (HB-612 
65) staining of MEFs 1 h after synchronous penetration from LEs were imaged by SIM. Blow-up of the 613 
nucleus and of two areas (i, ii) are shown. Scale bars; 10 µm. n=3 independent experiments gave similar 614 
results.  615 
(c) TNPO1-depletion inhibits vRNP nuclear import. NP (HB-65) staining of IAV-infected A549 cells at 4 616 
hpi. Scale bars; 10 µm. n=3 independent experiments gave similar results.  617 
(d) TNPO1 promotes M1-removal from cytoplasmic NP. Confocal images of IAV-infected A549 cells at 3 618 
hpi. stained with Hoechst (grey), NP (HB-65, green), M1 (polyclonal, red) and LAMP1 (blue). The insets 619 
(i, ii) show blow-ups of areas selected by broken-line square(s). Scale bars; 10 µm. n=3 independent 620 
experiments gave similar results.  621 
(e) Incoming M1 and NP colocalise in the cytoplasm of TNPO1-depleted cells. IAV-infected A549 cells 622 
(n=15) at 2.5 hpi were stained as in (d), imaged, and analysed automatically. The rank-weighted 623 
colocalisation index of M1 and NP spots excluding LAMP1 and nucleus is shown. n=2 independent 624 
experiments. 625 
(f) Cytoplasmic NP area is increased in TNPO1-depleted cells. IAV-infected A549 cells (n=15) at 2 and 626 
2.5 hpi were processed as in (e). n=2 independent experiments gave similar results. The mean and SD are 627 
shown. 628 
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(g) Cytoplasmic M1 intensity is increased in TNPO1-depleted cells. IAV-infected A549 cells (n=15) at 2 629 
and 2.5 hpi were processed as in (e). The experiments were repeated independently twice with similar 630 
results. The mean with 95% CI is shown. P value was determined using two-sided, unpaired t-test. 631 
(h) TNPO1 promotes M1-bypass uncoating. A549 cells were subjected to acid bypass fusion/hemifusion, 632 
M1-uncoating and vRNP import assays. The percentage of cells positive for DiOC18(3), dispersed M1 633 
(HB-64) staining, and nuclear NP was quantified for the fusion assay, M1 uncoating assay, and vRNP 634 
import assay, respectively. The mean and SD are shown (n=3). 635 
(i) Acid bypass IAV fusion/hemifusion is unaffected in TNPO1-depleted MDCK cells. Bypass (-)/(+) 636 
indicates pH 6.8- or pH 5.0-treated samples, respectively. Performed 3 days after shRNA induction. The 637 
mean is shown (n=2). 638 
(j) Acid bypass M1-uncoating is blocked in TNPO1-depleted MDCK cells. The mean and SD are shown 639 
(n=5). 640 
(k) Ectopic expression of GFP-human TNPO1 rescues acid bypass M1-uncoating in TNPO1-depleted 641 
MDCK cells. After 2 days of shRNA-induction cells were transfected with GFP or GFP-TNPO1, and 642 
subjected to acid bypass M1-uncoating assay 20 h later. The mean and SD are shown (n=3). P value was 643 
determined using two-sided, unpaired t-test. 644 
 645 
Fig. 3 TNPO1 binds to incoming IAV cores via a M1 N-terminal PY-NLS. 646 
(a) TNPO1 colocalises with incoming M1 and NP. Fifteen min after synchronous LE penetration in MEFs 647 
or HDAC6 -/- MEFs, cells were stained for TNPO1 (magenta), NP (HB-65, green), and M1 (polyclonal, 648 
cyan). Locations indicated by arrowheads are blown-up in the inset. Scale bars; 10 µm. n=3 independent 649 
experiments gave similar results.  650 
(b) TNPO1 co-precipitates with M1 from primed IAV. Purified X31 virions were non-primed (pH 7.0) or 651 
primed (pH 5.6, 120 mM[K+]) and subjected to a His-TNPO1 pull-down assay, analysed by SDS-PAGE 652 
and Western blotting. His-MBP was used as a negative control. n=3 independent experiments gave similar 653 
results.  654 
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(c) Sequence alignment of known PY-NLSs with the conserved IAV M1 N-terminal sequence. Epitope 1 655 
(a hydrophobic patch, containing the glycine), 2 (a basic patch) and 3 (PY) was adapted from 2, 27. 656 
(d) Glycine 18 is critical for IAV infection. IAV WSN strains (WT or G18A) were reverse genetically 657 
produced to infect A549 cells. Their infectivity was analysed by IIF against NP (HB-65). The mean and SD 658 
are shown (n=3). P value was determined using two-sided, unpaired t-test. 659 
(e) TNPO1 co-precipitates less efficiently with M1 from G18A virus compared to WT virus. Viruses were 660 
primed and precipitated with His-TNPO1 as in (b), and detected by SDS-PAGE and Western blotting. n=2 661 
independent experiments gave similar results.  662 
(f) Structure of G18A compared to WT M1-N (L1/L3 loops). Superposition of M1-N structures present in 663 
the Protein Data Bank that crystallised in the neutral pH face-to-back arrangement. G18A M1-N is shown 664 
as grey cartoon with selected residues as sticks in atom colours. PDB entries 1EA3 30 and 5V8A 31 are 665 
shown as cartoon models in blue and gold, respectively, with selected residues displayed as lines.  666 
(g) Detailed view of the G18A mutation with its electron density. L1/L3 loops of G18A M1-N are shown 667 
as sticks in grey and atom colours. A 2mFo-DFc simulated annealing omit electron density map is displayed 668 
in blue (1).  669 
(h) Surface representation of the L1-L3 region of M1-N highlighting the closing of a surface cavity in M1-670 
N G18A (grey, left) if compared with 1EA3 (blue, right). 671 
  672 
Fig. 4 673 
Model of step-wise IAV uncoating by HDAC6 and TNPO1 during cell entry. After viral uptake into 674 
endosomes, the M2 cation channels open resulting in influx of protons and K+ ions that loosens interactions 675 
stabilising the core. This triggers a conformational change in M1 that exposes the PY-NLS close to the N-676 
terminus. Following viral fusion in LEs, the core is exposed to cytosolic factors and HDAC6 binds to shell-677 
associated, unanchored ubiquitin chains via its zinc finger ubiquitin-binding domain (ZnF-UBP). HDAC6 678 
N-terminus binds to M1. Together with other components of the aggresome processing machinery such as 679 
motors dynein, myosin II, microtubules and actin filaments, HDAC6 releases the M1 shell from the 680 
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endosome surface and ruptures it. The eight bundled vRNPs are released into the cytosol. At the same time, 681 
TNPO1 associates with the PY-NLS exposed in the primed M1. TNPO1 removes residual M1 from the 682 
vRNP surface, which allows the dissociation of vRNPs from each other. KPNA and KPNB1 bind to the 683 
classical NLS in NP resulting in nuclear import of fully or partially debundled vRNPs. MTOC; microtubule 684 
organising centre. The figure was adapted from1. 685 
 686 
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Supplementary Figure 1 
Nucleocytoplasmic transport factor siRNA screen against IAV X31 in A549 cells. (a) The workflow 
of the nucleocytoplasmic transport factor siRNA screen performed in A549 cells using IAV X31 (an 
H3N2 reassorted strain derived from PR8 and A/Hong Kong/1/68 strains). Scale bar; 200 µm. (b) The 
import/export factor genes and (c) nuclear pore component genes that decreased IAV infection. Genes 
that were toxic upon depletion were removed. The mean and SD of the results of infection compared to 
control cells after depletion with three different siRNA oligos are shown. n=3 independent experiments. 
(d) The full list of genes targeted in the siRNA screen and the results of IAV infection upon their depletion. 
The average z-score value (log2 infection compared to the control) of the three different siRNA oligos 
are shown per gene.  
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Supplementary Figure 2 
TNPO1 is required for IAV X31 infection in HeLa cells. Cells were treated with AllStars Negative control, 
TNPO1, ATP6V1B2 siRNAs and infected with X31, fixed at 10 hpi. IAV infection was analysed by IIF 
against NP (HB-65).  n=3 independent experiments. The mean and SD are shown. 
 
 
 
 
 
  
Supplementary Figure 3 
TNPO1 promotes removal of residual M1 from penetrated cytoplasmic vRNPs. IAV (MOI=50) was 
allowed to enter A549 cells transfected with AllStars Negative control or TNPO1#3 siRNAs, subjected to 
synchronous LE penetration and fixed after 30 min. The cells were processed for IIF and stained for NP (HB-
65, green), M1 (polyclonal, red) and LAMP1 (blue). The open-lined circles indicate cytoplasmic NP spots 
devoid of significant LAMP1 staining, and their respective locations in the other two (red, blue) channels. 
The nuclei were stained with Hoechst (grey). Scale bars; 10 µm. The experiments were repeated 
independently three times with similar results. 
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 Supplementary Figure 4 
M9-NLS competes with TNPO1 for M1-uncoating. (a) Schematic showing the steps of acid bypass IAV 
entry assays i.e. fusion/hemifusion, M1-uncoating, vRNP import, and the representative data derived. (b) 
Depletion of TNPO1 and KPNB1 in A549 cells transfected with siRNAs. A549 cells were transfected with 
siRNAs for 3 days after which they were harvested and analysed by SDS-PAGE and Western blotting. The 
membrane used for TNPO1 detection was reblotted to detect CAS (which served as a loading control). For 
the KPNB1 blot, a non-specific band served as a loading control. The experiments were repeated three times 
with similar results. (c) TNPO1 overexpression increases M1-uncoating, whereas hnRNP A1 M9-NLS 
overexpression reduces M1-uncoating. The acid bypass M1-uncoating assay was performed in A549 cells 
transiently expressing GFP, GFP-TNPO1, GFP-M9-NLS, or GFP-M9-NLS mutant. The cells were fixed 3 
min after the pH 5.0 acid pulse, processed for IIF against M1 (HB-64) and the percentage of M1-positive 
cells were analysed by FACS. The P values were determined by two-sided, unpaired t-test. The mean and SD 
are shown. 
 Supplementary Figure 5 
TNPO1 co-precipitates with incoming IAV M1. (a) A549 cells were lysed and immunoprecipitated with 
anti-TNPO1 monoclonal antibody or mouse IgG as a negative control, subjected to SDS-PAGE, Western 
blotting and detected with anti-TNPO1. The IgG heavy chain (HC) is shown as a loading control. (b) IAV 
X31 was bound to A549 cells for 45 min on ice, washed, and incubated at 37°C in the absence or presence 
of 20mM NH4Cl for 2.5 h and lysed in CSK buffer. The lysates were immunoprecipitated with anti-TNPO1 
monoclonal antibody, subjected to SDS-PAGE, Western blotting, and detected with M1 (HB-64) and anti-
TNPO1 antibodies. The experiments were repeated independently twice with similar results. 
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Supplementary Figure 6  
IAV M1 N-terminus PY-NLS is the epitope of M1 monoclonal antibody HB-64 used for the M1-
uncoating assay. (a) The IAV M1 N-terminal sequence showing epitope 1 and 2 of the PY-NLS. (b) Gly18 
(and Pro19, Leu20 to a lesser degree) is the critical residue for M1 recognition by HB-64. Plasmids with 
single amino acid mutations in the hydrophobic patch (18-GPL-20) of epitope 1 were generated. HEK293T 
cells were transfected with plasmids expressing GFP-M1 WT, GFP-M1 G18A, GFP-M1 P19A, GFP-M1 
L20A or GFP-M1 K21A and harvested 24 h later. The cell lysates were subjected to SDS-PAGE and Western 
blotting, and detected with anti-GFP and anti-M1 (HB-64) antibodies. (c) HEK293T cells were transfected 
with the same plasmids as in (b) for 24 h, after which they were trypsinised, fixed, processed for FACS after 
staining with HB-64 and anti-mouse Alexa Fluor 647 secondary antibody. The scatter plots depict GFP (x-
axis) and HB-64 (y-axis) signal intensity. The experiments were repeated independently three times with 
similar results. 
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Supplementary Figure 7 
Structure of G18A M1-N. (a) Overall structure of the G18A M1 N-terminal domain. The structure is 
displayed in cartoon mode in two orientations rotated by 90° around the indicated axis and colored in rainbow 
colors from blue (N-terminus) to red (C-terminus) to highlight the topology. N-, C-termini, and helices are 
labeled. The position of the G18A mutation is labeled with an asterisk. (b) Neutral pH, crystallographic face-
to-back dimer of the G18A M1 N-terminal domain. The homodimer is presented as cartoon in two 
orientations rotated by 90° around the indicated axis. Monomers are colored in orange and blue. N-, C-
termini, and the position of the G18A mutation are labeled. Parts of the structured N-terminal affinity tag are 
omitted for clarity reasons. (c) Acidic pH, face-to-face dimer of the M1 N-terminal domain as present in PDB 
entry 1AA71. The homodimer is presented as cartoon in two orientations rotated by 90° around the indicated 
axis. Monomers are colored in orange and blue. N-, C-termini, and the position of the G18A mutation are 
labeled. 
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Supplementary Figure 8 
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